Loss widens sharply. Opus Genetics Inc. (NASDAQ: IRD) reported a loss of $0.80 per share for Q4 2025, significantly wider than the $0.23 loss posted in the year-ago quarter. The loss also deepened from the prior quarter’s $0.25 loss, marking a 220% sequential deterioration. The company recorded a net loss of $49.6 million on an operating loss of $38.6 million, reflecting the cash-intensive nature of early-stage biotechnology development.
Revenue surges on collaboration activity. Revenue reached $14.2 million, up 230% from $4.3 million in Q4 2024 and a dramatic 361% jump from the prior quarter’s $3.1 million. The sharp sequential acceleration suggests milestone payments or upfront collaboration fees, typical for biotech companies advancing clinical programs or securing partnerships. Trading volume reached 1.2 million shares as the stock held steady at $4.89, near its 52-week high of $5.10.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.